Pfizer’s Biosimilars Top $2.3bn In 2021
Biosimilars Business Expands By Over 50%; Sterile Injectables Grow To $5.7bn
Pfizer has continued to report growth in its biosimilars segment, with sales up by more than 50% in 2021 to $2.3bn. Meanwhile, a more modest increase has also been seen in the company’s sterile injectables business.
You may also be interested in...
Pfizer Quietly Chalks Up Another $2bn Year For Biosimilars
Despite annual sales that topped out at more than $2bn, Pfizer remains tight-lipped about its biosimilars interests as it looks towards a US launch this year of its Abrilada rival to Humira.
The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations
A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.
Pfizer’s Biosimilars Grow By A Tenth
Pfizer has reported healthy growth of a tenth for its biosimilars portfolio in the first half of 2022, at the same time as its sterile injectables sales slipped by a similar degree.